辅助免疫治疗对可切除非小细胞肺癌患者新辅助化疗免疫治疗后预后的影响：简要报告。

IF 3 Q2 ONCOLOGY

JTO Clinical and Research Reports Pub Date : 2025-01-01 DOI:10.1016/j.jtocrr.2024.100763

Yichen Dong MD , Long Xu MD , Jialiang Wen MD , Haojie Si MD , Juemin Yu MD , Tao Chen MD , Huikang Xie MD , Xinjian Li MD , Minglei Yang MD , Junqiang Fan MD , Junqi Wu MD , Yunlang She MD , Deping Zhao MD , Chang Chen MD, PhD

{"title":"辅助免疫治疗对可切除非小细胞肺癌患者新辅助化疗免疫治疗后预后的影响：简要报告。","authors":"Yichen Dong MD , Long Xu MD , Jialiang Wen MD , Haojie Si MD , Juemin Yu MD , Tao Chen MD , Huikang Xie MD , Xinjian Li MD , Minglei Yang MD , Junqiang Fan MD , Junqi Wu MD , Yunlang She MD , Deping Zhao MD , Chang Chen MD, PhD","doi":"10.1016/j.jtocrr.2024.100763","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>The potential survival benefits of adjuvant immunotherapy for resectable NSCLC after neoadjuvant chemoimmunotherapy, and the optimal number of adjuvant immunotherapy cycles, remain uncertain. This study aims to evaluate the prognostic impact of adjuvant immunotherapy and determine the optimal number of cycles.</div></div><div><h3>Methods</h3><div>A total of 438 patients who received neoadjuvant chemoimmunotherapy between August 2019 and June 2022 across four hospitals were enrolled in this study, with a median follow-up time of 31.3 months. Recurrence-free survival (RFS) and overall survival (OS) were estimated using Kaplan-Meier methods and tested by log-rank test. Unstratified Cox proportional hazards models were fitted to the subgroups.</div></div><div><h3>Results</h3><div>In this multi-center cohort, 29.7% of patients (n = 130) achieved a pathologic complete response. Patients who received adjuvant immunotherapy experienced significant survival benefits compared with those who did not (RFS: hazard ratio [HR] = 0.63, 95% confidence interval: 0.41–0.98, <em>p</em> = 0.037; OS: hazard ratio = 0.27, 95% confidence interval: 0.13–0.57, <em>p</em> < 0.001). Subgroup analyses found that patients with a squamous histologic type, positive PD-L1 expression, and those with a major pathologic response particularly benefited from adjuvant immunotherapy. In addition, we found that six cycles of adjuvant immunotherapy served as a threshold for better prognostic differentiation, suggesting that six or more cycles may be more beneficial.</div></div><div><h3>Conclusions</h3><div>Our study found that the addition of adjuvant immunotherapy to neoadjuvant chemoimmunotherapy is significantly associated with improved RFS and OS in patients with resectable NSCLC. We also identified that six cycles of adjuvant immunotherapy may be the optimal regimen for these patients.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 1","pages":"Article 100763"},"PeriodicalIF":3.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699361/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prognostic Impact of Adjuvant Immunotherapy in Patients With Resectable NSCLC After Neoadjuvant Chemoimmunotherapy: A Brief Report\",\"authors\":\"Yichen Dong MD , Long Xu MD , Jialiang Wen MD , Haojie Si MD , Juemin Yu MD , Tao Chen MD , Huikang Xie MD , Xinjian Li MD , Minglei Yang MD , Junqiang Fan MD , Junqi Wu MD , Yunlang She MD , Deping Zhao MD , Chang Chen MD, PhD\",\"doi\":\"10.1016/j.jtocrr.2024.100763\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>The potential survival benefits of adjuvant immunotherapy for resectable NSCLC after neoadjuvant chemoimmunotherapy, and the optimal number of adjuvant immunotherapy cycles, remain uncertain. This study aims to evaluate the prognostic impact of adjuvant immunotherapy and determine the optimal number of cycles.</div></div><div><h3>Methods</h3><div>A total of 438 patients who received neoadjuvant chemoimmunotherapy between August 2019 and June 2022 across four hospitals were enrolled in this study, with a median follow-up time of 31.3 months. Recurrence-free survival (RFS) and overall survival (OS) were estimated using Kaplan-Meier methods and tested by log-rank test. Unstratified Cox proportional hazards models were fitted to the subgroups.</div></div><div><h3>Results</h3><div>In this multi-center cohort, 29.7% of patients (n = 130) achieved a pathologic complete response. Patients who received adjuvant immunotherapy experienced significant survival benefits compared with those who did not (RFS: hazard ratio [HR] = 0.63, 95% confidence interval: 0.41–0.98, <em>p</em> = 0.037; OS: hazard ratio = 0.27, 95% confidence interval: 0.13–0.57, <em>p</em> < 0.001). Subgroup analyses found that patients with a squamous histologic type, positive PD-L1 expression, and those with a major pathologic response particularly benefited from adjuvant immunotherapy. In addition, we found that six cycles of adjuvant immunotherapy served as a threshold for better prognostic differentiation, suggesting that six or more cycles may be more beneficial.</div></div><div><h3>Conclusions</h3><div>Our study found that the addition of adjuvant immunotherapy to neoadjuvant chemoimmunotherapy is significantly associated with improved RFS and OS in patients with resectable NSCLC. We also identified that six cycles of adjuvant immunotherapy may be the optimal regimen for these patients.</div></div>\",\"PeriodicalId\":17675,\"journal\":{\"name\":\"JTO Clinical and Research Reports\",\"volume\":\"6 1\",\"pages\":\"Article 100763\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699361/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JTO Clinical and Research Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666364324001334\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTO Clinical and Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666364324001334","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的：可切除的非小细胞肺癌在新辅助化疗免疫治疗后，辅助免疫治疗的潜在生存益处，以及最佳的辅助免疫治疗周期数仍不确定。本研究旨在评估辅助免疫治疗对预后的影响，并确定最佳周期数。方法：在2019年8月至2022年6月期间，共有438名接受新辅助化疗免疫治疗的患者参与了这项研究，中位随访时间为31.3个月。采用Kaplan-Meier法估计无复发生存期（RFS）和总生存期（OS），采用log-rank检验。亚组采用无分层Cox比例风险模型拟合。结果：在这个多中心队列中，29.7%的患者（n = 130）达到了病理完全缓解。与未接受辅助免疫治疗的患者相比，接受辅助免疫治疗的患者获得了显著的生存益处(RFS：风险比[HR] = 0.63, 95%可信区间：0.41-0.98,p = 0.037；OS：风险比= 0.27,95%可信区间：0.13-0.57,p < 0.001)。亚组分析发现，具有鳞状组织类型、PD-L1阳性表达和主要病理反应的患者特别受益于辅助免疫治疗。此外，我们发现6个周期的辅助免疫治疗可以作为更好的预后分化的阈值，这表明6个或更多的周期可能更有益。结论：我们的研究发现，在新辅助化疗免疫治疗的基础上增加辅助免疫治疗与可切除的非小细胞肺癌患者的RFS和OS的改善显著相关。我们还发现，六个周期的辅助免疫治疗可能是这些患者的最佳方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Prognostic Impact of Adjuvant Immunotherapy in Patients With Resectable NSCLC After Neoadjuvant Chemoimmunotherapy: A Brief Report

Objective

The potential survival benefits of adjuvant immunotherapy for resectable NSCLC after neoadjuvant chemoimmunotherapy, and the optimal number of adjuvant immunotherapy cycles, remain uncertain. This study aims to evaluate the prognostic impact of adjuvant immunotherapy and determine the optimal number of cycles.

Methods

A total of 438 patients who received neoadjuvant chemoimmunotherapy between August 2019 and June 2022 across four hospitals were enrolled in this study, with a median follow-up time of 31.3 months. Recurrence-free survival (RFS) and overall survival (OS) were estimated using Kaplan-Meier methods and tested by log-rank test. Unstratified Cox proportional hazards models were fitted to the subgroups.

Results

In this multi-center cohort, 29.7% of patients (n = 130) achieved a pathologic complete response. Patients who received adjuvant immunotherapy experienced significant survival benefits compared with those who did not (RFS: hazard ratio [HR] = 0.63, 95% confidence interval: 0.41–0.98, p = 0.037; OS: hazard ratio = 0.27, 95% confidence interval: 0.13–0.57, p < 0.001). Subgroup analyses found that patients with a squamous histologic type, positive PD-L1 expression, and those with a major pathologic response particularly benefited from adjuvant immunotherapy. In addition, we found that six cycles of adjuvant immunotherapy served as a threshold for better prognostic differentiation, suggesting that six or more cycles may be more beneficial.

Conclusions

Our study found that the addition of adjuvant immunotherapy to neoadjuvant chemoimmunotherapy is significantly associated with improved RFS and OS in patients with resectable NSCLC. We also identified that six cycles of adjuvant immunotherapy may be the optimal regimen for these patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊